Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Locally Advanced Non-resectable Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: ixabepilone|DRUG: ixabepilone + cetuximab
Sponsor: R-Pharm